These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1916889)

  • 1. Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis.
    Spear GT; Sullivan BL; Takefman DM; Landay AL; Lint TF
    Immunology; 1991 Aug; 73(4):377-82. PubMed ID: 1916889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation by human monoclonal antibodies to human immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Zolla-Pazner S
    J Virol; 1993 Jan; 67(1):53-9. PubMed ID: 7677959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of complement on the surface of cells infected by human immunodeficiency virus.
    Spear GT; Landay AL; Sullivan BL; Dittel B; Lint TF
    J Immunol; 1990 Feb; 144(4):1490-6. PubMed ID: 1968081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classical pathway of complement activation in mammalian kidneys.
    Zwirner J; Felber E; Burger R; Bitter-Suermann D; Riethmüller G; Feucht HE
    Immunology; 1993 Oct; 80(2):162-7. PubMed ID: 8262545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection.
    Rattan A; Pawar SD; Nawadkar R; Kulkarni N; Lal G; Mullick J; Sahu A
    PLoS Pathog; 2017 Mar; 13(3):e1006248. PubMed ID: 28301559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
    Beebe DP; Schreiber RD; Cooper NR
    J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.
    Leddy JP; Simons RL; Douglas RG
    J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation by recombinant HIV-1 glycoprotein gp120.
    Süsal C; Kirschfink M; Kröpelin M; Daniel V; Opelz G
    J Immunol; 1994 Jun; 152(12):6028-34. PubMed ID: 7911492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV and complement: role of the complement system in HIV infection.
    Marschang P; Ebenbichler CF; Dierich MP
    Int Arch Allergy Immunol; 1994; 103(2):113-7. PubMed ID: 8292898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sendai virus infected cells are readily cytolysed by guinea-pig complement without antibody.
    Okada H; Okada N
    Immunology; 1981 Jun; 43(2):337-44. PubMed ID: 6265347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and human complement: inefficient virolysis and effective adherence.
    Bánki Z; Stoiber H; Dierich MP
    Immunol Lett; 2005 Mar; 97(2):209-14. PubMed ID: 15752560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin.
    Anders EM; Hartley CA; Reading PC; Ezekowitz RA
    J Gen Virol; 1994 Mar; 75 ( Pt 3)():615-22. PubMed ID: 8126457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auto-antibody dependent activation of the autologous classical complement pathway by guinea-pig red cells treated with influenza virus or neuraminidase: in vitro and in vivo study.
    Lambre CR; Thibon M; Le Maho S; Di Bella G
    Immunology; 1983 Jun; 49(2):311-9. PubMed ID: 6852870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.